Biosimilars for Hematologic Malignancies: Dissecting Real-World Evidence and Barriers to Utilization

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: July 28, 2021
Expiration Date: July 28, 2022

Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Join Dr. Bennett, Dr. Fishman, and Dr. Knopf as they explore real-world evidence and barriers to biosimilar drug use for hematologic malignancies. In this activity, they discuss the definition and parameters of biosimilars, evidence supporting biosimilar filgrastim, peg-filgrastim, and epoetin for hematologic malignancies, and challenges associated with biosimilar uptake and use, including safety, interchangeability, and extrapolation.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with hematologic malignancies.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify key scientific factors surrounding biosimilarity and drug interchangeability of biosimilar agents
  • Distinguish potential clinical and regulatory challenges to uptake of biosimilars for supportive care in patients with hematologic cancer
  • Outline and overcome barriers and care disparities related to uptake and adoption of biosimilars in comparison to their biologic originator drug


Biosimilars for Hematologic Malignancies: Dissecting Real-World Evidence and Barriers to Utilization – Charles L. Bennett, MD, PhD, MPP; Marc L. Fishman, MD, CM; Kevin Knopf, MD, MPH

Instructions for Participation and Credit

This activity is eligible for credit through July 28, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Charles L. Bennett, MD, PhD, MPP
Frank P. and Josie M. Fletcher Chair
SmartState Chair and Director
SmartState Center for Medication Safety and Efficacy
University of South Carolina
Columbia, South Carolina

Dr. Charles Bennett received his medical degree from the University of Pennsylvania School of Medicine, and his PhD and master’s degree in public policy from the RAND Graduate School in Santa Monica. He is the Frank P. and Josie M. Fletcher Chair, and the SmartState Chair and Director of the SmartState Center for Medication Safety and Efficacy at the University of South Carolina. Dr. Bennett was the first physician to hold the AC Buehler Chair of Economics and Medicine at the Northwestern University Kellogg School of Management and the Feinberg School of Medicine.

Dr. Bennett, an academic hematologist/oncologist, has been the principal investigator for more than $15 million dollars in peer-reviewed grant support from the NIH, VA, the American Cancer Society, and the Pfizer Foundation. He was one of the original nine principal investigators for the NCI-funded U01 research project. He has led seven R01-funded research grants on pharmaceutical safety, this funding has supported the Southern Network on Adverse Reactions (SONAR) project at the University of South Carolina. He is currently the principal investigator of the American Cancer Society Institutional Research Grant at the University of South Carolina. In addition, Dr. Bennett has served on two National Academy of Medicine seminal projects – as a member of the Unequal Burden of Cancer, and as a consultant of Crossing the Quality Chasm. He has published more than 450 articles in peer-reviewed medical journals including the New England Journal of Medicine, JAMA, JAMA Oncology, Lancet, Blood, Journal of Clinical Oncology, Lancet Oncology, and The Oncologist.

Marc L. Fishman, MD, CM
Assistant Adjunct Professor
University of South Carolina College of Pharmacy
Columbia, South Carolina
Oncology Analytics, Inc.
Plantation, Florida

Dr. Marc  Fishman received his medical education at McGill University, Montreal, Canada. He completed his internship at Jewish General Hospital, and his residency in internal medicine at  Royal Victoria Hospital, Montreal. In addition, he completed a fellowship in hematology-oncology at McGill University teaching hospitals. Dr. Fishman is an Assistant Adjunct Professor at the University of South Carolina College of Pharmacy. He is Executive Chairman and Chairman of the Board of Directors at  Oncology Analytics, which he founded in 2008, and is also founder of Soluciones Analiticas de Salud, a Puerto Rico subsidiary of Oncology Analytics. As a hematologist, oncologist and patient advocate, Dr. Fishman recognized that the rising costs and complexity of cancer treatment were compromising the ability for oncologists to make comprehensive, evidenced-based decisions for their patients’ treatment.

Dr. Fishman is board certified in internal medicine and hematology and developed his perspective on healthcare management and funding mechanisms through a wide variety of clinical experiences, including work in Kenya, New Zealand, Canada, Australia, and the United States. His 20+ years of clinical treatment experience and exposure to multi-national health systems has reinforced his commitment to value-based care and a patient first approach, which measures the efficacy, toxicity and affordability of cancer treatment options, which put the patient in a position to achieve the best possible outcome

Kevin Knopf, MD, MPH
Assistant Clinical Professor
University of California, San Francisco
Division Chief of Hematology/Oncology
Highland Hospital
Oakland, California

Dr. Kevin Knopf received his medical degree at the University of California, San Francisco School of Medicine. He completed his clinical training at Northwestern Medical School, Sloan Kettering Cancer Center, received an MPH in epidemiology and statistics at Johns Hopkins School of Public Health, and also trained at the National Cancer Institute Medicine Branch and the Health Services and Economics Research Branch. Dr. Knopf is currently Assistant Clinical Professor at the University of California, San Francisco, Division Chief of Hematology/Oncology at Highland Hospital, Oakland, California, as well as Associate Professor of Pharmaco-economics at the University of South Carolina School of Pharmacy. In addition, he is a member of the Institute for Health Policy. As a health economist and health services researcher, Dr. Knopf’s research focuses on cost-effectiveness, patterns and quality of care in oncology, and health disparities in cancer screening, diagnosis, and treatment.


MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-032-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Charles Bennett has disclosed no relevant financial relationships. .

Dr. Marc Fishman has disclosed no relevant financial relationships.

Dr. Kevin Knopf has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Scott J. Hershman, MD, FACEHP, CHCP, Educational Program Director, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Pfizer, Inc.

©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.